NCT01040728 - A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol (BI1744) Low

Low dose inhaled orally once daily from Respimat inhaler

DRUG

Olodaterol (BI1744) High

High dose inhaled orally once daily from Respimat inhaler

DRUG

Tiotropium 18 mcg

18 mcg inhaled once daily from HandiHaler

DRUG

Placebo (for Olodaterol (BI1744)l)

Placebo (olodaterol low and high dose) delivered by Respimat

DRUG

Placebo (for Tiotropium)

Placebo (Tiotropium 18 mcg) delivered by HandiHaler

Trial Locations (12)

1222.40.11003 Boehringer Ingelheim Investigational Site, Jasper

1222.40.11001 Boehringer Ingelheim Investigational Site, Clearwater

1222.40.11002 Boehringer Ingelheim Investigational Site, Tampa

1222.40.49401 Boehringer Ingelheim Investigational Site, Berlin

1222.40.49403 Boehringer Ingelheim Investigational Site, Berlin

1222.40.49402 Boehringer Ingelheim Investigational Site, Hanover

1222.40.31003 Boehringer Ingelheim Investigational Site, Breda

1222.40.31002 Boehringer Ingelheim Investigational Site, Eindhoven

1222.40.31001 Boehringer Ingelheim Investigational Site, Heerlen

1222.40.47003 Boehringer Ingelheim Investigational Site, Arendal

1222.40.47002 Boehringer Ingelheim Investigational Site, Drammen

1222.40.47001 Boehringer Ingelheim Investigational Site, Trondheim